VIRPAX PHARMACEUTICALS INC (VRPX) Fundamental Analysis & Valuation

NASDAQ:VRPX • US9282512063

Current stock price

0.6695 USD
-0.55 (-45.12%)
At close:
0.4498 USD
-0.22 (-32.82%)
After Hours:

This VRPX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. VRPX Profitability Analysis

1.1 Basic Checks

  • VRPX had negative earnings in the past year.
  • VRPX had a negative operating cash flow in the past year.
  • In the past 5 years VRPX always reported negative net income.
  • In the past 5 years VRPX always reported negative operating cash flow.
VRPX Yearly Net Income VS EBIT VS OCF VS FCFVRPX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

  • With a Return On Assets value of -775.73%, VRPX is not doing good in the industry: 95.48% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -775.73%
ROE N/A
ROIC N/A
ROA(3y)-347.85%
ROA(5y)-401.45%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
VRPX Yearly ROA, ROE, ROICVRPX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for VRPX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VRPX Yearly Profit, Operating, Gross MarginsVRPX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. VRPX Health Analysis

2.1 Basic Checks

  • VRPX has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for VRPX has been increased compared to 5 years ago.
  • There is no outstanding debt for VRPX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
VRPX Yearly Shares OutstandingVRPX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 5M 10M
VRPX Yearly Total Debt VS Total AssetsVRPX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

  • Based on the Altman-Z score of -90.57, we must say that VRPX is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -90.57, VRPX is not doing good in the industry: 93.47% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -90.57
ROIC/WACCN/A
WACCN/A
VRPX Yearly LT Debt VS Equity VS FCFVRPX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M 30M

2.3 Liquidity

  • A Current Ratio of 0.63 indicates that VRPX may have some problems paying its short term obligations.
  • VRPX has a worse Current ratio (0.63) than 92.96% of its industry peers.
  • A Quick Ratio of 0.63 indicates that VRPX may have some problems paying its short term obligations.
  • The Quick ratio of VRPX (0.63) is worse than 88.44% of its industry peers.
Industry RankSector Rank
Current Ratio 0.63
Quick Ratio 0.63
VRPX Yearly Current Assets VS Current LiabilitesVRPX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. VRPX Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 59.22% over the past year.
EPS 1Y (TTM)59.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-412.82%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 22.53% on average over the next years. This is a very strong growth
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y81.21%
EPS Next 2Y35.96%
EPS Next 3Y22.53%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
VRPX Yearly Revenue VS EstimatesVRPX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 50M 100M 150M
VRPX Yearly EPS VS EstimatesVRPX Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 -50 -100 -150 -200

More info and screens

Find the best growth stocksShow best growing peers

1

4. VRPX Valuation Analysis

4.1 Price/Earnings Ratio

  • VRPX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VRPX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VRPX Price Earnings VS Forward Price EarningsVRPX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VRPX Per share dataVRPX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -5 -10 -15

4.3 Compensation for Growth

  • VRPX's earnings are expected to grow with 22.53% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.96%
EPS Next 3Y22.53%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. VRPX Dividend Analysis

5.1 Amount

  • No dividends for VRPX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

VRPX Fundamentals: All Metrics, Ratios and Statistics

VIRPAX PHARMACEUTICALS INC

NASDAQ:VRPX (4/3/2025, 8:04:03 PM)

After market: 0.4498 -0.22 (-32.82%)

0.6695

-0.55 (-45.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-03
Earnings (Next)N/A
Inst Owners0.72%
Inst Owner Change0%
Ins Owners0.14%
Ins Owner Change0%
Market Cap856.96K
Revenue(TTM)N/A
Net Income(TTM)-12.07M
Analysts43.33
Price TargetN/A
Short Float %0.97%
Short Ratio0
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-84.28%
Min EPS beat(2)-190.49%
Max EPS beat(2)21.93%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-2400%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-1622.22%
EPS NY rev (3m)-1622.22%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-5.29
EYN/A
EPS(NY)-15.81
Fwd EYN/A
FCF(TTM)-13.06
FCFYN/A
OCF(TTM)-13.06
OCFYN/A
SpS0
BVpS-0.71
TBVpS-0.71
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -775.73%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-347.85%
ROA(5y)-401.45%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.63
Quick Ratio 0.63
Altman-Z -90.57
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)59.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-412.82%
EPS Next Y81.21%
EPS Next 2Y35.96%
EPS Next 3Y22.53%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y23.01%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-69.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-69.61%
OCF growth 3YN/A
OCF growth 5YN/A

VIRPAX PHARMACEUTICALS INC / VRPX Fundamental Analysis FAQ

What is the ChartMill fundamental rating of VIRPAX PHARMACEUTICALS INC (VRPX) stock?

ChartMill assigns a fundamental rating of 0 / 10 to VRPX.


What is the valuation status for VRPX stock?

ChartMill assigns a valuation rating of 1 / 10 to VIRPAX PHARMACEUTICALS INC (VRPX). This can be considered as Overvalued.


Can you provide the profitability details for VIRPAX PHARMACEUTICALS INC?

VIRPAX PHARMACEUTICALS INC (VRPX) has a profitability rating of 0 / 10.


What is the financial health of VIRPAX PHARMACEUTICALS INC (VRPX) stock?

The financial health rating of VIRPAX PHARMACEUTICALS INC (VRPX) is 0 / 10.


What is the expected EPS growth for VIRPAX PHARMACEUTICALS INC (VRPX) stock?

The Earnings per Share (EPS) of VIRPAX PHARMACEUTICALS INC (VRPX) is expected to grow by 81.21% in the next year.